Tags

Type your tag names separated by a space and hit enter

Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Parkinsonism Relat Disord. 2005 Mar; 11(2):131-3.PR

Abstract

Elevated plasma homocysteine (Hcy) concentrations have been reported in L-dopa treated Parkinson's disease (PD) patients, suggesting that L-dopa treatment is an acquired cause of hyperhomocysteinemia. Aim of this study is to evaluate the effects of different antiparkinsonian drugs on Hcy concentrations. We compared Hcy, B(12) and folate levels in 45 PD patients (15 treated with dopamine-agonists, 15 with L-dopa and 15 with L-dopa plus a catechol-O-methyltransferase-inhibitor (COMT-I) and in 15 controls. Analysis of data revealed that L-dopa administration significantly increases Hcy concentrations and that the addition of COMT-I effectively reduces the homocysteinemia.

Authors+Show Affiliations

Department of Neurological Sciences, University of Bari, Ospedale Policlinico, Piazza Giulio Cesare 11, Bari 70124, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

15734674

Citation

Zoccolella, S, et al. "Plasma Homocysteine Levels in Parkinson's Disease: Role of Antiparkinsonian Medications." Parkinsonism & Related Disorders, vol. 11, no. 2, 2005, pp. 131-3.
Zoccolella S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord. 2005;11(2):131-3.
Zoccolella, S., Lamberti, P., Armenise, E., de Mari, M., Lamberti, S. V., Mastronardi, R., Fraddosio, A., Iliceto, G., & Livrea, P. (2005). Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism & Related Disorders, 11(2), 131-3.
Zoccolella S, et al. Plasma Homocysteine Levels in Parkinson's Disease: Role of Antiparkinsonian Medications. Parkinsonism Relat Disord. 2005;11(2):131-3. PubMed PMID: 15734674.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. AU - Zoccolella,S, AU - Lamberti,P, AU - Armenise,E, AU - de Mari,M, AU - Lamberti,S V, AU - Mastronardi,R, AU - Fraddosio,A, AU - Iliceto,G, AU - Livrea,P, Y1 - 2004/12/20/ PY - 2004/04/06/received PY - 2004/06/18/revised PY - 2004/07/15/accepted PY - 2005/3/1/pubmed PY - 2005/7/16/medline PY - 2005/3/1/entrez SP - 131 EP - 3 JF - Parkinsonism & related disorders JO - Parkinsonism Relat Disord VL - 11 IS - 2 N2 - Elevated plasma homocysteine (Hcy) concentrations have been reported in L-dopa treated Parkinson's disease (PD) patients, suggesting that L-dopa treatment is an acquired cause of hyperhomocysteinemia. Aim of this study is to evaluate the effects of different antiparkinsonian drugs on Hcy concentrations. We compared Hcy, B(12) and folate levels in 45 PD patients (15 treated with dopamine-agonists, 15 with L-dopa and 15 with L-dopa plus a catechol-O-methyltransferase-inhibitor (COMT-I) and in 15 controls. Analysis of data revealed that L-dopa administration significantly increases Hcy concentrations and that the addition of COMT-I effectively reduces the homocysteinemia. SN - 1353-8020 UR - https://www.unboundmedicine.com/medline/citation/15734674/Plasma_homocysteine_levels_in_Parkinson's_disease:_role_of_antiparkinsonian_medications_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1353-8020(04)00124-5 DB - PRIME DP - Unbound Medicine ER -